trial

Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia

NCTId NCT00654706
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 264 (actual)
Sponsored by H. Lundbeck A/S
Primary completion 2010-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
264 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-03
Primary completion
2010-01
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
SertindoleQuetiapine

Sponsors

H. Lundbeck A/SLead Sponsor

Sites

26 total
Garden Grove, United StatesNational City, United StatesPasadena, United StatesPico Rivera, United StatesSan Diego, United StatesStanford, United StatesTorrance, United StatesAurora, United StatesOrange City, United StatesTampa, United StatesAtlanta, United StatesChicago, United States

Linked catalysts

1
Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparato — primary completion2010-01

Facts & assertions

4 sourced
Enrollment
264
Phase
PHASE3
Primary Completion Date
2010-01
Status
COMPLETED
relationships
The graph out of here
drug
Sertindole
drug
Quetiapine
drug
lead_sponsor
H. Lundbeck A/S
company
indication
Schizophrenia
indication
Schizophrenia
indication
Cognition
indication